-
Targeting AXL inhibits the growth and metastasis of prostate cancer in bone.
07 Feb 2025 13:07 GMT
… prostate cancer metastatic to the bone is invariably lethal, although treatment with docetaxel … potentially synergizing with docetaxel and carboplatin … expression in human prostate cancer bone metastases was … in combination with docetaxel or carboplatin …
-
Enzalutamide and Docetaxel in Combination With Androgen Deprivation for Men With Metastatic Hormone-Sensitive Prostate Cancer: ENZADA, a Phase II Trial.
07 Feb 2025 13:07 GMT
… inhibitors (ARPI) in combination with docetaxel (Doc) and androgen deprivation therapy … men with metastatic hormone sensitive prostate cancer (mHSPC). We hypothesized that combining …
-
Metastatic Castration-Resistant Prostate Cancer Market to See Unprecedented Growth by 2034 | DelveInsight
05 Feb 2025 13:08 GMT
… cases of Prostate cancer
• Age-specific cases of Prostate cancer
• Total cases of Prostate cancer by … therapies include sipuleucel-T, chemotherapy (docetaxel or cabazitaxel), abiraterone acetate, enzalutamide …
-
Genomic biomarkers of survival in patients with metastatic hormone-sensitive prostate cancer undergoing intensified androgen deprivation therapy.
03 Feb 2025 11:58 GMT
… receptor pathway inhibitors (ARPI), docetaxel or both has been shown … patients with metastatic hormone-sensitive prostate cancer (mHSPC). Currently, baseline tumor … , patient counseling, and prognostication.
Prostate cancer and prostatic diseases. 2025 Jan …
-
Prostate Cancer Bone Metastasis: Molecular Mechanisms of Tumor and Bone Microenvironment
01 Feb 2025 10:18 GMT
… prostate tumors in the bone microenvironment. Mesenchymal stem cells induce already disseminated prostate cancer … prostate cancer suppressor.127 Additionally, prostate cancer cells treated with Wnt5a show resistance to docetaxel … prostate tumor … prostate tumours …
-
Treatment algorithm following first-line therapy failure in metastatic prostate cancer.
23 Jan 2025 11:11 GMT
… with metastatic castration-resistant prostate cancer (mCRPC) following the … of hormone-sensitive prostate cancer, the management of … ), chemotherapeutics such as docetaxel and cabazitaxel, as … (ARPI), Chemotherapeutika wie Docetaxel und Cabazitaxel, als auch …
-
Validation of an Artificial Intelligence-Based Prognostic Biomarker in Patients with Oligometastatic Castration-Sensitive Prostate Cancer - Beyond the Abstract
22 Jan 2025 23:00 GMT
… oligometastatic castration-sensitive prostate cancer (omCSPC), an … (ARSI) or docetaxel.
The primary objective … therapy for oligometastatic prostate cancer recurrence (STOMP): … oligometastatic Castration-Sensitive prostate cancer. Radiotherapy and Oncology …
-
Lutetium-177 PSMA radioligand therapy in taxan-naive first- and second-line metastatic castration resistant prostate cancer after first-line ARPI therapy.
14 Jan 2025 11:24 GMT
… vs. 57% ARPI vs. 33% docetaxel. Mostly no significant baseline differences … treatment, relative to ARPI or docetaxel treatment and may be considered … Main, Frankfurt, Germany., Martini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf …
-
Hormone Sensitive Advanced Prostate Cancer Treatment Market 2032: FDA Approvals, Clinical Trials, drugs by DelveInsight
08 Jan 2025 12:39 GMT
… Sensitive Advanced Prostate Cancer Overview
Hormone-sensitive advanced prostate cancer (HSPC) refers to prostate cancer that … (e.g., docetaxel) to improve outcomes.
Advances in understanding prostate cancer biology have …
-
Current Status of Sequential Treatment for Castration-resistant Prostate Cancer: A Retrospective Analysis.
07 Jan 2025 08:59 GMT
… patients diagnosed with castration-resistant prostate cancer at Showa University Hospital … enzalutamide) and anticancer drugs (docetaxel and cabazitaxel). We investigated the … receptor signal inhibitor-docetaxel (n=85), docetaxel-androgen receptor signal …
About
© 1995-2025